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ALLERGIC rhinoconjunctivitis is the most common atopic
condition encountered in clinical practice. Analysis of
the pathogenesis of this condition permits identification
of optimal therapeutic targets. The increased knowledge
ofthe underlying pathophysiology suggests that multiple
inflammatory mediators are involved in the pathogenesis
of the allergic reaction in the ocular and nasal mucosa’.
However, despite the presence of a wide range of differ-
ent mediators, it would appear that histamine plays a key
role. Experimental allergen challenge studies have dem-
onstrated that histamine is the only mediator which pro-
duces the full spectrum of clinical manifestations of the
acute allergic reaction when applied to the mucosal sur-
face. While both HI- and H2-receptors are present in the
nasal and ocular mucosa, only Hi-receptor antagonists
are capable of inhibiting histamine-induced symptoms of
allergic rhinoconjunctivitis. Furthermore, although the
exact role of histamine in the immediate and prolonged
allergic reaction has not yet been fully elucidated, these
findings do not exclude the possibility that histamine is
involved in these processes. The available evidence there-
fore supports current clinical practice for use of HI-
receptor antagonist as a first-line therapy in patients with
this atopic condition.
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Allergic rhinitis
Allergic rhinitis is the most common form of aller-
gic disease encountered in clinical practice, afflicting
approximately 10-20% of the general population,
with the available epidemiological data indicating
that the prevalence of this condition is increasing.
2,3
Allergic rhinitis may be seasonal or perennial. Sea-
sonal allergic rhinitis, also known as hayfever, is
caused by sensitivity to aeroallergens such as
pollens. Triggering allergens for perennial allergic
rhinitis are house dust mite, animal dander and
mould. Seasonal and perennial allergic rhinitis dis-
play similar symptomatology, with both conditions
characterised by nasal itching, sneezing, congestion
and rhinorrhoea. However, symptoms of perennial
allergic rhinitis tend to be less severe, except under
conditions of high allergen exposure.
The past decade has witnessed an increasing inter-
est and understanding of the inter-relationship be-
tween the upper and lower respiratory tract. In some
patients it seems that allergic rhinitis may predispose
to the development of asthma, the most serious
manifestation of airway allergy,3,5 suggesting that
allergic rhinitis should therefore be regarded as a risk
factor for development of generalised airway disease.
This is further implied by the common association
between allergic rhinitis and bronchial
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hyperreactivity. Recent data also suggest that asthma
symptoms may improve with appropriate treatment
of nasal symptoms in patients with concomitant
rhinitis and asthma.7,8
The nasal mucosa shares several structural similari-
ties with the tracheobronchial mucosa, most notably
the respiratory epithelium with its basement mem-
brane and the adjacent submucosa containing
microvessels and glands. Perhaps more importantly,
a number of functional similarities also exist.1 Stud-
ies of nasal pathology may therefore also serve to
illustrate the process of pathophysiological events
occurring in the lower airways.
The nose provides excellent opportunities for
studies of the functional aspects of the mucosal
allergic reaction. The accessibility of the nasal
mucosa enables well controlled provocation with
various kinds of stimuli and permits the mucosal
responses to be equally well monitored by harvest-
ing and analysis of surface liquids, cells and biopsy
specimens.
Anatomical aspects of the nasal mucosa
The nasal airway is covered by a squamous epithe-
lium in the anterior part of the nose and by a ciliated
pseudostratified epithelium in the remaining part of
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the cavities. The latter type of epithelium consists of
at least four different cell types: ciliated columnar
cells, non-ciliated columnar cells, goblet cells and
basal cells. The epithelial cells rest on a basement
membrane and the apical lateral portions are con-
nected with tight junctions. The goblet cells and the
serous and seromucous glands contribute to the
production of the airway surface liquids which cover
the mucosal surface. Further sources are plasma
solutes which enter the lumen at mucosal exudation
processes, and condensed water recovered from
exhaled air.
The nasal mucosa is supplied by sympathetic and
parasympathetic nerves, and by sensory nerves
which run in the trigeminal nerve. Stimulation of
these sensory C-fibres gives rise to nasal itching and
sneezing. The presence of neuropeptides has been
demonstrated in both the autonomic and sensory
nerves using immunohistochemical techniques.
11,12
Histamine-induced itching and sneezing can be
abolished by topical treatment with Hi-receptor an-
tagonists, but not with Hi-antagonists, indicating the
presence and function of Hi-receptors in the nasal
mucosa. 13
The human nasal mucosa has a well developed
capillary network. This includes a subepithelial layer
of capillaries, which partly are of a fenestrated type. TM
Cavernous sinusoids situated in the deepest parts of
the lamina propria15 regulate the mucosal blood con-
tent. In the lower part of the lamina propria, arterio-
venous shunts allow the blood to bypass the capil-
lary network, and it has been suggested that these
shunts may be involved in nasal thermoregulation.
6
Normally, exchange of solutes occurs across the
capillary endothelium. However, when the mucosa is
inflamed, the endothelium of the postcapillary
venules regulates the plasma exudation process,
iv
The presence of venous sinusoids, which are very
abundant in the nose, has also recently been demon-
strated in the bronchi.
18
The allergic reaction
The nasal mucosa contains dendritic cells
(Langerhans cells) which appear to be capable of
presenting aeroallergenic proteins to mucosal
immunocompetent cells leading to IgE-production.9
These IgE antibodies bind to high-affinity receptors
on mast cells and basophils in the nasal mucosa, and
perhaps also at low affinity receptors on other cells,
such as monocytes, eosinophils and platelets.
2-22 On
renewed allergen/mucosal contact, the allergen
crosslinks two or more IgE molecules on the surface
of these cells initiating the production and release of
a number of biochemical mediators and other bio-
logical substances such as cytokines. The released
substances act on.local cells and sensory nerve end-
ings leading to increased nasal congestion, watery
and proteinic rhinorrhoea, sneezing and nasal itch-
ing. These symptoms characterize the immediate al-
lergic reaction and tend to diminish very rapidly.
Symptoms such as increased nasal patency, occa-
sional sneezing and minor nasal secretion may how-
ever persist for a longer period of time. The duration
and severity of these symptoms appears to be highly
individual and may also be related to both the initial
dose of allergen and the sensitivity of the atopic
individual. A biphasic allergic response has also been
documented in some patients characterized by an
immediate allergic response followed some hours
later by a recurrence of symptoms and a repeated
mucosal output of mediators known as a late phase
reaction. 23 Functionally, this prolonged allergic in-
flammator response is characterized by increased
mucosal reactivity to rechallenge with allergen (’spe-
cific reactivity’) or to ’nonspecific stimuli’ such as
histamine or methacholine. 24,25 The timing of this
increase in nasal reactivity generally corresponds to
an influx and activation of inflammatory cells into the
superficial part of the nasal mucosa. ’6
This increased responsiveness of hyperreactivity to
rechallenge with the specific allergen and other
nonspecific stimuli is seen not only during experi-
mental nasal provocation studies (Fig. 1), but also in
clinical disease,
iv a phenomenon known as prim-
ing.
28 Studies in patients with active allergic rhinitis
have shown that symptom severity is greater at the
end of the pollen season for a given degree of pollen
exposure compared to that experienced earlier in the
season.
The pathophysiological events occurring during
continuous allergic disease such as natural hayfever
are probably much more complicated than any of the
above experimentally-induced reactions. It seems
likely that an escalating mixture of the immediate
response, prolonged symptoms, late phase response
and mucosal hyperreactivity to both allergen and
nonspecific stimuli contribute to the symptoms seen
during natural disease.
Metachromatic cells
The mast cell is believed to play a central role in
the development of the allergic reaction. Activation
of these metachromatic cells, triggered by the bind-
ing of allergen to IgE, leads to release of granule-
associated mediators, including histamine, from pre-
formed cytoplasmic granules and lipid mediators
from intracellular lipid bodies,29,3 as well as to tran-
scription and synthesis of cytokines. 31
The role of the mast cell in healthy individuals is
not clear, but it has been suggested that it may be
involved in the regulation of the growth and differ-
entiation of other cells.2 Our understanding of the
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FIG 1. Severity of sneezing (upper panel), composite nasal symptom
scores (middle panel) and TAME-esterase levels (lower panel) in nasal
lavage fluid after challenge with increasing doses of pollen allergen and
histamine (0.1 mg). Patients were rechallenged after 24 h with the lowest
dose of allergen and the same dose of histamine. As seen, mucosal
reactivity to both allergen and histamine was increased (n 13). *p < 0.05,
**p < 0.01 and ***p < 0.001 (day 2 vs day 1).
function of this cell is further complicated by findings
which would suggest the presence of a specific
mucosal mast cell type. 33
In vitro stimulation of the mast cell leads to com-
plex intracytoplasmic changes including the forma-
tion of degranulation channels and solubilization of
matrix materials prior to the development of multiple
openings to the exterior of the degranulation chan-
nels. 34 Ultrastructural studies of mast cells have dem-
onstrated that the nasal mucosal mast cells are redis-
tributed from their normal pre-seasonal habitat in the
stroma into the epithelium during natural pollen
exposure, a phenomenon known as intra-epithelial
migration.5,6 The migratory capacity of the mast cell
has also been demonstrated after nasal allergen chal-
lenge.7 In contrast, the migratory capacity of the
blood basophil during seasonal disease is controver-
sial. Some authors have reported an increased
number of blood basophils during natural pollen
exposure,8 while other studies have failed to confirm
these changes. 35,36 However, these discrepancies may
partly be due to methodological differences.
Our _understanding of the involvement of the mast
cell in the pathophysiology of allergic rhinitis has
been further derived from the measurement of
mediators in nasal lavage fluid. Following allergen
challenge in sensitized individuals, increased levels
of mediators with a specific mast cell origin such as
tryptase and prostaglandin D are found in nasal
washings.9-41 Levels of other mediators which may
originate from mast cells, as well as from other cells
in the nasal mucosa, also increase after local allergen
challenge. These include histamine42 and
leukotrienes.4
Histamine
Histamine ([-imidazolethylamine) is an
intracellular mediator which exerts a wide range
of functions on a variety of target tissues via its
effects on H1- and Hi-receptors. Produced by
decarboxylat.ion of histidine, histamine is wide-
spread in mammalian tissues. Histamine is one of the
major mediators of the immediate hypersensitivity
reaction.44-4 Histamine is also an important mediator
in the central nervous system and gastric mucosa.47
Histamine is stored in large amounts in
metachromatic granules of mast cells and basophils
and is rapidly metabolized by one of two enzymatic
pathways, either histamine N-methyltransferase or
oxidation.48
There has been increased interest and research
concerning the role of potential mediators such as
platelet activating factor, leukotrienes, bradykinins
and neurogenic mediators in the pathogenesis of the
allergic reaction in recent years. However, histamine
is still the only mediator which mimics the full spec-
trum of nasal symptoms of the immediate allergic
response when topically applied to the nasal
mucosa. Furthermore, although both H- and H2-
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FIG 2. Schematic overview of the effects of histamine on end-organs in the
nasal mucosa.
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receptors are present in the nasal mucosa, only HI-
receptor antagonists are capable of inhibiting this
histamine-induced response. As shown in Fig. 2, the
effects of histamine in the nose are mediated through
binding to receptors on the endothelial cells, vascu-
lar smooth muscles and sensory nerves inducing
exudation of plasma, vasodilatation, sneezing and
nasal itching, respectively.49 Histamine also induces a
reflex-mediated parasympathetic glandular secretion
in the nasal mucosa.5
Further support for the importance of the mast cell
and histamine in the pathogenesis of allergic rhinitis
is provided by observations during seasonal disease.
Indirect evidence, supported by ultrastructural find-
ings, for mast cell histamine secretory activity has
been documented during the pollen season. A strong
relationship has been reported between mucosal
tissue concentrations of histamine and the severity of
nasal symptoms experienced during the pollen
season, with a positive correlation between the pre-
seasonal number of nasal mast cells and the severity
of nasal symptoms during seasonal disease has also
been reported. 51
Although the effects of histamine resemble the
effects of allergen in the early allergic reaction, his-
tamine does not, in contrast to allergen, attract and
activate eosinophils. Neither does histamine induce
increased reactivity of the nasal mucosa to specific or
nonspecific stimuli. 52 Furthermore, at present, our
knowledge about interactions between histamine
and other cells which may be important for the
orchestration of allergic airway inflammation, includ-
ing Langerhans cells, T-lymphocytes and epithelial
cells, is limited. However, these findings do not
exclude the possibility that histamine is associated
with both the immediate and prolonged allergic
reaction.
Allergic conjunctivitis
Allergic conjunctivitis is the most common ocular
allergic disorder. Symptoms are typically bilateral,
and often simultaneously with allergic rhinitis. How-
ever, allergic conjunctivitis can also be present as an
isolated manifestation of atopic disease. 53 Conjuncti-
val provocations were performed by Blackley as
early as the end of the 19th century. 54 Although
ocular experimental allergen challenge studies are
performed less frequently than nasal challenges,
the available evidence suggests that the
pathophysiological mechanisms underlying allergic
conjunctivitis and rhinitis are very similar. The pat-
tern of mediators and plasma exudation markers
recently observed after allergen challenge of the
conjunctiva has previously been demonstrated in
allergic rhinitis; consisting of increased levels of
kinins, TAME-esterase, albumin and ryptase, indica-
tive of mast cell activation. 55,56 Mast cells have also
been identified in conjunctival biopsies from allergic
individuals and increased numbers of eosinophils
appear in the tear fluid some hours after local aller-
gen challenge. 57 Topical application of histamine to
the conjunctiva induces redness and itching, two
typical symptoms of allergic conjunctivitis. More
pronounced symptoms include swelling of the eye
lids which may even develop into a periorbital
oedema. 58
Implications for patient management
Recent years have witnessed an increasing under-
standing of the pathophysiology of allergic
rhinoconjunctivitis, particularly concerning the po-
tential role of inflammatory mediators, cytokines and
inflammatory cells. Histamine appears to play a key
role, being the only mediator which induces the full
spectrum of clinical manifestations of the immediate
allergic reaction when topically applied to the
mucosal surface. Coupled with the well-documented
efficacy of HI-receptor antagonists in the treatment of
allergic rhinoconjunctivitis, these findings provide a
pathophysiological rationale for the current clinical
practice for use of antihistamines as a therapy in
patients with ocular and nasal allergies.
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